S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69

Blueprint Medicines Stock Forecast, Price & News

-2.57 (-2.55%)
(As of 11/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
570,340 shs
Average Volume
326,111 shs
Market Capitalization
$5.78 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BPMC News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

Blueprint Medicines logo

About Blueprint Medicines

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$793.73 million
Cash Flow
$5.61 per share
Book Value
$26.38 per share


Net Income
$313.88 million
Net Margins
Pretax Margin




Free Float
Market Cap
$5.78 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.08 out of 5 stars

Medical Sector

508th out of 1,392 stocks

Pharmaceutical Preparations Industry

236th out of 670 stocks

Analyst Opinion: 2.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions

Is Blueprint Medicines a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 4 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Blueprint Medicines stock.
View analyst ratings for Blueprint Medicines
or view top-rated stocks.

How has Blueprint Medicines' stock price been impacted by Coronavirus (COVID-19)?

Blueprint Medicines' stock was trading at $52.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BPMC stock has increased by 87.5% and is now trading at $98.28.
View which stocks have been most impacted by COVID-19

Are investors shorting Blueprint Medicines?

Blueprint Medicines saw a decrease in short interest in the month of October. As of October 29th, there was short interest totaling 2,380,000 shares, a decrease of 15.0% from the October 14th total of 2,800,000 shares. Based on an average daily trading volume, of 366,600 shares, the short-interest ratio is currently 6.5 days. Approximately 4.1% of the shares of the company are short sold.
View Blueprint Medicines' Short Interest

When is Blueprint Medicines' next earnings date?

Blueprint Medicines is scheduled to release its next quarterly earnings announcement on Wednesday, February 16th 2022.
View our earnings forecast for Blueprint Medicines

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) issued its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported ($2.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.63) by $0.37. The biotechnology company had revenue of $24.19 million for the quarter, compared to the consensus estimate of $42.58 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 30.19% and a negative net margin of 383.58%. Blueprint Medicines's revenue for the quarter was down 96.8% compared to the same quarter last year. During the same quarter last year, the company posted $11.16 earnings per share.
View Blueprint Medicines' earnings history

What guidance has Blueprint Medicines issued on next quarter's earnings?

Blueprint Medicines issued an update on its FY 2021 earnings guidance on Thursday, November, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $170 million-$180 million, compared to the consensus revenue estimate of $148.37 million.

What price target have analysts set for BPMC?

11 Wall Street analysts have issued twelve-month target prices for Blueprint Medicines' shares. Their forecasts range from $95.00 to $152.00. On average, they expect Blueprint Medicines' stock price to reach $122.30 in the next twelve months. This suggests a possible upside of 24.4% from the stock's current price.
View analysts' price targets for Blueprint Medicines
or view top-rated stocks among Wall Street analysts.

Who are Blueprint Medicines' key executives?

Blueprint Medicines' management team includes the following people:

What is Jeff Albers' approval rating as Blueprint Medicines' CEO?

5 employees have rated Blueprint Medicines CEO Jeff Albers on Glassdoor.com. Jeff Albers has an approval rating of 100% among Blueprint Medicines' employees. This puts Jeff Albers in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.83%), Wellington Management Group LLP (5.44%), William Blair Investment Management LLC (2.92%), TimesSquare Capital Management LLC (2.50%), Alliancebernstein L.P. (2.37%) and Macquarie Group Ltd. (2.20%). Company insiders that own Blueprint Medicines stock include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Marion Dorsch, Mark Alan Goldberg, Nicholas Lydon and Tracey L Mccain.
View institutional ownership trends for Blueprint Medicines

Which institutional investors are selling Blueprint Medicines stock?

BPMC stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Morgan Stanley, Farallon Capital Management LLC, TimesSquare Capital Management LLC, Deerfield Management Company L.P. Series C, Balyasny Asset Management LLC, Tudor Investment Corp Et Al, and Millennium Management LLC. Company insiders that have sold Blueprint Medicines company stock in the last year include Ariel Hurley, Charles A Rowland Jr, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, and Tracey L Mccain.
View insider buying and selling activity for Blueprint Medicines
or view top insider-selling stocks.

Which institutional investors are buying Blueprint Medicines stock?

BPMC stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, William Blair Investment Management LLC, Boxer Capital LLC, Fisher Asset Management LLC, Dimensional Fund Advisors LP, Point72 Asset Management L.P., Panagora Asset Management Inc., and Macquarie Group Ltd..
View insider buying and selling activity for Blueprint Medicines
or or view top insider-buying stocks.

How do I buy shares of Blueprint Medicines?

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $98.28.

How much money does Blueprint Medicines make?

Blueprint Medicines has a market capitalization of $5.78 billion and generates $793.73 million in revenue each year. The biotechnology company earns $313.88 million in net income (profit) each year or ($7.11) on an earnings per share basis.

How many employees does Blueprint Medicines have?

Blueprint Medicines employs 429 workers across the globe.

What is Blueprint Medicines' official website?

The official website for Blueprint Medicines is www.blueprintmedicines.com.

Where are Blueprint Medicines' headquarters?

Blueprint Medicines is headquartered at 45 SIDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (617) 374-7580 or via email at [email protected].

This page was last updated on 11/30/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.